CHDM
MCID: CHR072
MIFTS: 61

Chordoma (CHDM) malady

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Chordoma

About this section
Sources:
12diseasecard, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Chordoma:

Name: Chordoma 52 48 24 25 54 70 12 50 39 68
Chordoma, Susceptibility to 52 27
Notochordal Sarcoma 25 54
Chdm 25 70
 
Chordoepithelioma 25
Chordocarcinoma 25
Notochordoma 25

Characteristics:

Orphanet epidemiological data:

54
chordoma:
Inheritance: Autosomal dominant,Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adult; Age of death: any age

HPO:

64
chordoma:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 215400
Orphanet54 ORPHA178
MESH via Orphanet40 D002817
UMLS via Orphanet69 C0008487
ICD10 via Orphanet31 C76.7
MedGen37 C0008487
MeSH39 D002817

Summaries for Chordoma

About this section
NIH Rare Diseases:48 A chordoma is a rare tumor that develops from cells of the notochord, a structure that is present in the developing embryo and is important for the development of the spine. the notochord usually disappears before birth, though a few cells may remain embedded in the bones of the spine or at the base of the skull. chordomas can occur anywhere along the spine. approximately half of all chordomas occur at the base of the spine; approximately one third occur at the base of the skull. chordomas grow slowly, extending gradually into the surrounding bone and soft tissue. the actual symptoms depend on the location of the chordoma. a chordoma at the base of the skull may lead to double vision and headaches. a chordoma that occurs at the base of the spine may cause problems with bladder and bowel function. chordomas typically occur in adults between the ages of 40 and 70. in many cases, the cause of the chordoma remains unknown. recent studies have shown that changes in the t gene have been associated with chordomas in a small set of families. in these families an inherited duplication of the t gene is associated with an increased risk of developing a chordoma. the current treatment is often the surgical removal of the tumor, followed by radiotherapy. last updated: 11/9/2016

MalaCards based summary: Chordoma, also known as chordoma, susceptibility to, is related to chondroid chordoma and clivus chordoma, and has symptoms including abnormality of the head, abnormality of the vertebral column and chordoma. An important gene associated with Chordoma is CHDM (Chordoma), and among its related pathways are Advanced glycosylation endproduct receptor signaling and Cytoskeleton remodeling Neurofilaments. Affiliated tissues include bone, lung and pituitary, and related mouse phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased cell migration.

Genetics Home Reference:25 A chordoma is a rare type of cancerous tumor that can occur anywhere along the spine, from the base of the skull to the tailbone. Chordomas grow slowly, gradually extending into the bone and soft tissue around them. They often recur after treatment, and in about 40 percent of cases the cancer spreads (metastasizes) to other areas of the body, such as the lungs.

OMIM:52 Chordomas are rare, clinically malignant tumors derived from notochordal remnants. They occur along the length of the... (215400) more...

UniProtKB/Swiss-Prot:70 Chordoma: Rare, clinically malignant tumors derived from notochordal remnants. They occur along the length of the spinal axis, predominantly in the sphenooccipital, vertebral and sacrococcygeal regions. They are characterized by slow growth, local destruction of bone, extension into adjacent soft tissues and rarely, distant metastatic spread.

Wikipedia:71 Chordoma is a rare slow-growing neoplasm thought to arise from cellular remnants of the notochord. The... more...

Related Diseases for Chordoma

About this section

Diseases related to Chordoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 239)
idRelated DiseaseScoreTop Affiliating Genes
1chondroid chordoma12.2
2clivus chordoma12.2
3spinal chordoma12.2
4clivus chondroid chordoma12.1
5sacrum chordoma12.1
6cervicitis10.4
7lucey-driscoll syndrome10.3MUC1, S100B
8secondary pulmonary hemosiderosis10.3MUC1, S100B
9inflammatory linear verrucous epidermal nevus10.3DES, VIM
10glucosidase acid-1,4-alpha deficiency10.3DES, GFAP
11ovarian insufficiency due to fsh resistance10.3MET, MUC1, VIM
12chondrosarcoma10.3
13postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma10.3MUC1, S100B, VIM
14subglottis verrucous carcinoma10.3MUC1, S100B, VIM
15conjunctival cancer10.3MUC1, S100B, VIM
16clear cell ependymoma10.3MUC1, S100B, VIM
17differentiating neuroblastoma10.2CDH1, MUC1, VIM
18endometrial stromal sarcoma10.2GFAP, MUC1, VIM
19benign schwannoma10.2S100B, VIM
20lymphomatous thyroiditis10.2DES, VIM
21precursor t-lymphoblastic lymphoma/leukemia10.2EGFR, MUC1, S100B
22marfanoid hypermobility syndrome10.2DES, MUC1, VIM
23childhood brain germinoma10.2MUC1, S100B, VIM
24cauda equina intradural extramedullary astrocytoma10.2GFAP, MUC1, VIM
25desmoid tumor10.2MUC1, S100B, VIM
26sclerosing hemangioma10.2CDH1, EGFR, MUC1
27petrous apex meningioma10.2DES, MUC1, VIM
28adult brainstem gliosarcoma10.2GFAP, MET, VIM
29myelinoclastic diffuse sclerosis10.2GFAP, MUC1, S100B
30coronary stenosis10.2DES, MUC1, VIM
31sebaceous adenoma10.2DES, MUC1, VIM
32anal gland neoplasm10.2DES, MUC1, VIM
33urethral cancer10.2DES, MET, VIM
34trombiculiasis10.2GFAP, MUC1, S100B
35omodysplasia 210.2DES, MUC1, VIM
36cervical lymphoepithelioma-like carcinoma10.2EGFR, MUC1
37bladder adenocarcinoma10.2CDKN2A, MUC1, VIM
38congenital muscular dystrophy with hyperlaxity10.2DES, MUC1, VIM
39porokeratosis10.2GFAP, MUC1, S100B
40breast squamous cell carcinoma10.2GFAP, MUC1, VIM
41avian influenza10.2CDKN2A, MUC1, VIM
42lung benign neoplasm10.2DES, MUC1, VIM
43orthostatic proteinuria10.2DES, MUC1, VIM
44his bundle tachycardia10.2EGFR, S100B, VIM
45dental caries10.2CDH1, EGFR, MUC1
46nasal cavity disease10.2CDH1, EGFR, MUC1
47vagina leiomyosarcoma10.2DES, GFAP, MUC1
48bronchitis10.2CDH1, GFAP
49hypogonadotropic hypogonadism-retinitis pigmentosa syndrome10.2GFAP, S100B, VIM
50thymic dysplasia10.2MUC1, NCAM1

Graphical network of the top 20 diseases related to Chordoma:



Diseases related to chordoma

Symptoms & Phenotypes for Chordoma

About this section

Symptoms by clinical synopsis from OMIM:

215400

Clinical features from OMIM:

215400

Human phenotypes related to Chordoma:

 64
id Description HPO Frequency HPO Source Accession
1 abnormality of the head64 HP:0000234
2 abnormality of the vertebral column64 HP:0000925
3 chordoma64 HP:0010762

GenomeRNAi Phenotypes related to Chordoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00210-A8.9EGFR, JUP, MUC1, PTEN, VIM
2GR00055-A-18.6EGFR, JUP, MET, MUC1, NCAM1, VIM

MGI Mouse Phenotypes related to Chordoma according to GeneCards Suite gene sharing:

41 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053917.5CDKN2A, EGFR, GFAP, MET, NCAM1, PTEN
2MP:00020067.3CDH1, CDKN2A, EGFR, LGALS3, MET, PDGFRA
3MP:00053897.3CDH1, CDKN2A, EGFR, LGALS3, PDGFRA, PTEN
4MP:00028737.0CDH1, EGFR, GFAP, JUP, MET, PDGFRA
5MP:00053886.8CDKN2A, EGFR, JUP, LGALS3, MET, PDGFRA
6MP:00053806.7CDH1, CDKN2A, EGFR, JUP, MET, PDGFRA
7MP:00053696.7CDKN2A, DES, EGFR, GFAP, JUP, MET
8MP:00053866.6CDKN2A, DES, GFAP, LGALS3, MET, NCAM1
9MP:00053816.3CDH1, CDKN2A, EGFR, GFAP, LGALS3, MET
10MP:00107716.1CDH1, CDKN2A, EGFR, JUP, LGALS3, PDGFRA
11MP:00053876.1CDH1, CDKN2A, EGFR, GFAP, JUP, LGALS3
12MP:00036315.9CDKN2A, EGFR, GFAP, JUP, LGALS3, MET
13MP:00053855.5CDH1, CDKN2A, DES, EGFR, GFAP, JUP
14MP:00053845.4CDH1, CDKN2A, DES, EGFR, GFAP, JUP
15MP:00053765.4CDH1, CDKN2A, DES, EGFR, GFAP, JUP
16MP:00107685.2CDH1, CDKN2A, DES, EGFR, GFAP, JUP

Drugs & Therapeutics for Chordoma

About this section

Drugs for Chordoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 2510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
TrioxsalenapprovedPhase 2, Phase 1413902-71-45585
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
Trimethylpsoralen
Trioxisaleno
 
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
trimethylpsoralen
trioxysalen
trisoralen
3
nivolumabapprovedPhase 2, Phase 1424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
4
Dasatinibapproved, investigationalPhase 2285302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
5
PalbociclibapprovedPhase 2127571190-30-211431660, 5005498, 5330286
Synonyms:
2euf
571190-30-2
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
 
Ibrance
Kinome_3823
Kinome_3824
LQQ
PD 0332991
PD 332991, PD 0332991, PD0332991
PD-0332991
PD-332991
PD0332991
Palbociclib
S1116_Selleck
6Imatinib MesylatePhase 2, Phase 1600123596
7Protein Kinase InhibitorsPhase 2, Phase 13689
8Angiogenesis Modulating AgentsPhase 24185
9Angiogenesis InhibitorsPhase 24257
10Immunosuppressive AgentsPhase 2, Phase 113086
11HematoporphyrinsPhase 2, Phase 114
12Pharmaceutical SolutionsPhase 28192
13Photosensitizing AgentsPhase 2, Phase 1492
14Hematoporphyrin DerivativePhase 2, Phase 130
15EtherPhase 2, Phase 161
16Antibodies, MonoclonalPhase 2, Phase 14039
17AntibodiesPhase 2, Phase 16394
18ImmunoglobulinsPhase 2, Phase 16394
19VaccinesPhase 26611
20Dermatologic AgentsPhase 2, Phase 15806
21Dihematoporphyrin EtherPhase 2, Phase 141
22
CobaltPhase 21677440-48-4104729
Synonyms:
Aquacat
Co
 
Cobalt-59
Cobatope-57
Kobalt
Super cobalt
23Brewer's YeastNutraceuticalPhase 237
24lysineNutraceuticalPhase 2, Phase 198
25
Panobinostatapproved, investigationalPhase 1135404950-80-76918837
Synonyms:
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
FT-0083488
Faridak
 
LBH 589
LBH-589
LBH-589B
LBH589
MolPort-005-933-338
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
nchembio.313-comp11
panobinostat
26
Cyclophosphamideapproved, investigationalPhase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
27
Busulfanapproved, investigationalPhase 154555-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
28
LenograstimapprovedPhase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
29
ThiotepaapprovedPhase 122652-24-45453
Synonyms:
 
Thioplex
30
MelphalanapprovedPhase 1729148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
31
Amifostineapproved, investigationalPhase 18120537-88-62141
Synonyms:
Amifostina
Amifostine
Amifostine Ethiofos
Amifostinum
Aminopropylaminoethyl Thiophosphate
 
Apaetp
Ethiofos
Ethyol
Gammaphos
SAPEP
WR-1065
32Protective AgentsPhase 17443
33Histone Deacetylase InhibitorsPhase 1569
34Adjuvants, ImmunologicPhase 12554
35MitogensPhase 11617
36Alkylating AgentsPhase 14827
37Antineoplastic Agents, AlkylatingPhase 14603
38Antirheumatic AgentsPhase 110956
39Radiation-Protective AgentsPhase 1480
40Liver ExtractsPhase 14067
41
Hyaluronic acidapproved, vet_approved4699004-61-953477741, 24759
Synonyms:
Hyaluronan
Hyaluronate
Hyaluronic acid
Hylartil
Hyruan Plus
Luronit
 
Macronan
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sofast
Synvisc
42
Mentholapproved26062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
43Blood Substitutes253
44Viscosupplements390
45Povidone169
46Plasma Substitutes240
47Misonidazole22
48Anti-Infective Agents22062
49Antiparasitic Agents2199
50Antiprotozoal Agents2051

Interventional clinical trials:

(show all 42)
idNameStatusNCT IDPhase
1Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
2Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull BaseRecruitingNCT01182779Phase 3
3Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant TumorsNot yet recruitingNCT02838602Phase 3
4Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical SpineUnknown statusNCT00592748Phase 1, Phase 2
5Efficacy and Safety of Imatinib in ChordomaCompletedNCT00150072Phase 2
6Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasCompletedNCT00474994Phase 2
7Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
8Ion Irradiation of Sacrococcygeal ChordomaRecruitingNCT01811394Phase 2
9Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT TracersRecruitingNCT02802969Phase 2
10The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, ChordomaRecruitingNCT02383498Phase 2
11Proton Radiation for Chordomas and ChondrosarcomasRecruitingNCT01449149Phase 1, Phase 2
12A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone SarcomasRecruitingNCT02389244Phase 2
13A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial SarcomaRecruitingNCT02601950Phase 2
14Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
15Photodynamic Therapy (PDT) For Recurrent High Grade GliomasRecruitingNCT01966809Phase 2
16Proton Beam Therapy for Chordoma PatientsActive, not recruitingNCT00496119Phase 2
17Trial of Dasatinib in Advanced SarcomasActive, not recruitingNCT00464620Phase 2
18CDK4/6 Inhibition in Locally Advanced/Metastatic ChordomaNot yet recruitingNCT03110744Phase 2
19Afatinib in Locally Advanced and Metastatic ChordomaNot yet recruitingNCT03083678Phase 2
20Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS CancersNot yet recruitingNCT03173950Phase 2
21Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent ChordomaUnknown statusNCT01175109Phase 1
22Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib MesylateCompletedNCT01046487Phase 1
23Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaRecruitingNCT02989636Phase 1
24A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaRecruitingNCT02601937Phase 1
25HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid TumorsRecruitingNCT00931931Phase 1
26Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard TherapiesRecruitingNCT01924689Phase 1
27Photodynamic Therapy (PDT) for Recurrent Pediatric Brain TumorsRecruitingNCT01682746Phase 1
28Nilotinib With Radiation for High Risk ChordomaActive, not recruitingNCT01407198Phase 1
29Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid TumorsTerminatedNCT00003926Phase 1
30Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With CancerUnknown statusNCT00349024
31Chordoma Family StudyCompletedNCT00410670
32Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma FamiliesCompletedNCT00341627
33Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With ChordomasCompletedNCT00713037
34Proton Therapy for Chordomas and/or ChondrosarcomasCompletedNCT00797602
35Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue SarcomasCompletedNCT01567046
36Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility GenesRecruitingNCT01200680
37Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized DiseaseRecruitingNCT02986516
38A Study of IMRT in Primary Bone and Soft Tissue SarcomaRecruitingNCT02520128
39Effect of High Doses of Radiation on Bone Structure and MetabolismRecruitingNCT02323295
40Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue SarcomaRecruitingNCT00919269
41High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of SkullActive, not recruitingNCT01346124
42Stereotactic Body Radiotherapy for Spine TumorsActive, not recruitingNCT01347307

Search NIH Clinical Center for Chordoma


Cochrane evidence based reviews: chordoma

Genetic Tests for Chordoma

About this section

Genetic tests related to Chordoma:

id Genetic test Affiliating Genes
1 Chordoma27 24

Anatomical Context for Chordoma

About this section

MalaCards organs/tissues related to Chordoma:

36
Bone, Lung, Pituitary, Thyroid, Endothelial, Lymph node, Breast

Publications for Chordoma

About this section

Articles related to Chordoma:

(show top 50)    (show all 783)
idTitleAuthorsYear
1
Whole-Body MRI Virtual Autopsy Using Diffusion-weighted Imaging With Background Suppression (DWIBS) at 3 T in a Child Succumbing to Chordoma. (28060123)
2017
2
Spinal stereotactic body radiotherapy following intralesional curettage with separation surgery for initial or salvage chordoma treatment. (28041314)
2017
3
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. (27696380)
2017
4
Osseous metastases of chordoma: imaging and clinical findings. (28064345)
2017
5
Prognostic Factors and Survival Outcomes in Patients with Chordoma in the United States: A Population-Based Analysis. (28457925)
2017
6
EM proves invaluable in the confirmation of chordoma in the sacral mass of a middle-aged man. (28524812)
2017
7
Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma. (28432450)
2017
8
UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. (28430034)
2017
9
A Case of Coincidental Intrasellar Chordoma and Pituitary Adenoma. (28516081)
2017
10
Erratum to: Symptom burden and life challenges reported by adult chordoma patients and their caregivers. (28527124)
2017
11
Erratum. UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. (28524794)
2017
12
Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients. (28368502)
2017
13
Clival chordoma: a single-centre outcome analysis. (28478512)
2017
14
Variables affecting functional improvement in chordoma patients admitted to an inpatient rehabilitation facility: A retrospective review. (28464722)
2017
15
On a Rare Cutaneous Metastasis from a Sacrococcygeal Chordoma. (28409046)
2017
16
MR Imaging Grading System for Skull Base Chordoma. (28428207)
2017
17
Recurrent chordoma with orbital and eyelid invasion. (28357494)
2017
18
Pediatric Clival Chordoma: A Curable Disease that Conforms to Collins' Law. (28521059)
2017
19
Updated Outcome and Analysis of Tumor Response in Mobile Spine and Sacral Chordoma Treated With Definitive High-Dose Photon/Proton Radiation Therapy. (27986348)
2017
20
Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients. (28059654)
2017
21
Answer to the Letter to the Editor of J. Li et al. concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917). (27766429)
2017
22
Chordoma Occurs in Young Children With Tuberous Sclerosis. (28498973)
2017
23
Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis. (28437876)
2017
24
Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917. (27757683)
2017
25
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. AA retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression FranAsaise (ANOCEF). (28478340)
2017
26
In Reply: Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. (28379552)
2017
27
Laser interstitial thermal therapy for palliative ablation of a chordoma metastasis to the spine: case report. (28362211)
2017
28
In Reply to "Prognostic Significance of Resection Degree inA Skull Base Chordoma: A Systematic Review and Meta-Analysis". (28437877)
2017
29
Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. (27161248)
2016
30
Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis. (27158344)
2016
31
Tumor size as a Prognostic Factor in Spinal Chordoma: A Systematic Literature Review. (27753788)
2016
32
Fine needle aspiration cytology aided diagnosis of chordoma at an unusual site. (27018015)
2016
33
Whole-transcriptome analysis of chordoma of the skull base. (27401718)
2016
34
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR. (27200287)
2016
35
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). (27659533)
2016
36
High-intensity focused ultrasonic ablation of sacral chordoma is feasible: a series of four cases and details of a national clinical trial. (27936948)
2016
37
Giant chordoma in the thoracolumbar spine: a case report and literature review. (27900552)
2016
38
CORR Insights(Ar): What are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients with Sacral Chordoma? (27184140)
2016
39
Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures. (27491867)
2016
40
PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma. (27002766)
2016
41
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. (27822356)
2016
42
Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute. (27942938)
2016
43
Immunotherapy as a Potential Treatment for Chordoma: a Review. (27475804)
2016
44
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. (27172898)
2016
45
Upregulation of metastasis-associated PRL-3 initiates chordoma in zebrafish. (26846972)
2016
46
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. (27558389)
2016
47
Genomic aberrations frequently alter chromatin regulatory genes in chordoma. (27072194)
2016
48
An unusual case of acquired pedophilic behavior following compression of orbitofrontal cortex and hypothalamus by a Clivus Chordoma. (27159984)
2016
49
Factors for tumor progression in patients with skull base chordoma. (27546605)
2016
50
Prognostic Biomarkers in Spinal Chordoma: A Systematic Review. (27941139)
2016

Variations for Chordoma

About this section

Copy number variations for Chordoma from CNVD:

6 (show top 50)    (show all 470)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
113362101135374737LossPTENChordoma
21337217122200000LossNF1Chordoma
31337317122200000LossP53Chordoma
41379511151400000LossWT1Chordoma
51381019163811651GainBAXChordoma
61381119163811651GainTGFB1Chordoma
71382518176117153LossSMAD4Chordoma
8174031142600000180300000GainChordoma
921008115600000106368585LossChordoma
10216541316000000114142980LossBRCA2Chordoma
11216551316000000114142980LossRBChordoma
12257391193800000243700000GainChordoma
1328392172220000078774742GainHER2Chordoma
142928912300000124300000LossRUNX3Chordoma
153107412522600125291501LossRUNX3Chordoma
163134812697957526979875GainChordoma
173173313024567130246671GainChordoma
183190113189933431900334LossChordoma
193190813194031531941315GainChordoma
203203113271974532720045GainChordoma
213203213272003632721036LossChordoma
223220713445134634452346GainChordoma
233267513839955038400550GainChordoma
243277013926412239265122GainChordoma
253396615099200250993002GainChordoma
2635065115970000074900000GainMEN1Chordoma
273603617090172070902020LossChordoma
283603817099838170998681LossChordoma
293607517113772871138728GainChordoma
304831211112700000LossChordoma
314958111108093558108239826LossATMChordoma
3252925112170000048800000LossChordoma
3356520115990000068400000LossChordoma
346373612120700000125900000LossChordoma
3565974122368523024715380GainSOX5Chordoma
3666550123070000035800000LossChordoma
37676771243829014414522GainCCND2Chordoma
38678471245433084554780GainChordoma
3968279124836674748398285GainCOL2A1Chordoma
407431113103858404103859404LossChordoma
418141414102320080102321080GainChordoma
428183514104931320104931620GainChordoma
438183614104931398104932398LossChordoma
4486968146789203367893033LossChordoma
4586969146789468567895685GainChordoma
4686990146827123268272232GainChordoma
4787006146840833268409332GainChordoma
4887676147586412775864427LossChordoma
4987678147588700575888005GainChordoma
5087692147618426376185263LossChordoma

Expression for genes affiliated with Chordoma

About this section
Search GEO for disease gene expression data for Chordoma.

Pathways for genes affiliated with Chordoma

About this section

Pathways related to Chordoma according to GeneCards Suite gene sharing:

(show all 30)
idSuper pathwaysScoreTop Affiliating Genes
19.9LGALS3, S100B
2
Show member pathways
9.6DES, GFAP, VIM
39.6CDH1, VIM
49.6NCAM1, PDGFRA, T
59.5LGALS3, MUC1, NCAM1
6
Show member pathways
9.4EGFR, GFAP, S100B
79.2MET, NCAM1, T, VIM
89.1EGFR, GFAP, LGALS3, VIM
99.0CDH1, MET, NCAM1
109.0CDH1, JUP, MET
119.0GFAP, NCAM1, PDGFRA, S100B, VIM
12
Show member pathways
8.9CDH1, EGFR, MET
138.9CDH1, EGFR, MET
148.9CDH1, EGFR, MET
158.9CDH1, EGFR, MET
168.8CDH1, JUP, MUC1, NCAM1
178.8CDKN2A, EGFR, PDGFRA
18
Show member pathways
8.7EGFR, MET, PDGFRA, PTEN
198.7EGFR, MET, PDGFRA, PTEN
20
Show member pathways
8.7EGFR, MET, PDGFRA, PTEN
218.7EGFR, MET, PDGFRA, PTEN
228.6CDH1, DES, JUP, MUC1, VIM
23
Show member pathways
8.5CDH1, CDKN2A, EGFR
24
Show member pathways
8.4CDH1, EGFR, JUP, PTEN
258.3CDKN2A, EGFR, PDGFRA, PTEN
267.6CDKN2A, EGFR, MET, PDGFRA, PTEN, VIM
27
Show member pathways
7.2CDH1, CDKN2A, EGFR, MET, PDGFRA, PTEN
286.8CDH1, CDKN2A, EGFR, JUP, MET, PDGFRA
29
Show member pathways
6.1CDH1, EGFR, JUP, LGALS3, MET, MUC1
30
Show member pathways
6.1CDH1, CDKN2A, DES, EGFR, GFAP, MET

GO Terms for genes affiliated with Chordoma

About this section

Cellular components related to Chordoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1fascia adherensGO:000591610.6DES, JUP
2catenin complexGO:001634210.3CDH1, JUP
3intermediate filamentGO:000588210.0DES, GFAP, JUP, VIM
4cytoplasmic side of plasma membraneGO:00098989.7CDH1, JUP, PTEN
5extracellular regionGO:00055767.5CDH1, EGFR, JUP, LGALS3, MET, MUC1
6cytoplasmGO:00057376.1CDH1, CDKN2A, DES, EGFR, GFAP, JUP
7plasma membraneGO:00058866.1CDH1, DES, EGFR, JUP, LGALS3, MET

Biological processes related to Chordoma according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1intermediate filament organizationGO:004510910.6DES, VIM
2cellular response to indole-3-methanolGO:007168110.2CDH1, JUP
3entry of bacterium into host cellGO:003563510.1CDH1, MET
4learning or memoryGO:00076119.9EGFR, PTEN, S100B
5phosphatidylinositol phosphorylationGO:00468549.9EGFR, MET, PDGFRA
6regulation of phosphatidylinositol 3-kinase signalingGO:00140669.8EGFR, MET, PDGFRA
7MAPK cascadeGO:00001659.5EGFR, MET, NCAM1, PDGFRA
8single organismal cell-cell adhesionGO:00163379.5CDH1, EGFR, JUP
9phosphatidylinositol-mediated signalingGO:00480159.3EGFR, MET, PDGFRA, PTEN
10positive regulation of cell proliferationGO:00082849.2EGFR, PDGFRA, PTEN, S100B, T
11transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.2EGFR, MET, PDGFRA

Molecular functions related to Chordoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor receptor bindingGO:000516110.3PDGFRA, PTEN
2structural constituent of cytoskeletonGO:000520010.1DES, GFAP, VIM
3phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:00469349.8EGFR, MET, PDGFRA
4glycoprotein bindingGO:00019489.8CDH1, EGFR, VIM
5protein phosphatase bindingGO:00199039.7EGFR, JUP, MET
6Ras guanyl-nucleotide exchange factor activityGO:00050889.4EGFR, MET, NCAM1, PDGFRA
7transmembrane receptor protein tyrosine kinase activityGO:00047149.2EGFR, MET, PDGFRA
8identical protein bindingGO:00428029.0DES, EGFR, GFAP, PTEN, S100B, VIM

Sources for Chordoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet